Additional analysis of data from a Phase 1b clinical trial that included all patients treated with gedatolisib combined with fulvestrant and palbociclib showed median progression-free survival (“PFS”) ...
HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback